obinutuzumab
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Genetic Implications:
Pronunciation:
oh-bi-nue-tooz-ue mab
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Gazyva
Ther. Class.
Pharm. Class.
monoclonal antibodies
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., and Cynthia A. Sanoski. "Obinutuzumab." Davis's Drug Guide, 20th ed., F.A. Davis Company, 2026. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110125/11/obinutuzumab.
Vallerand AHA, Sanoski CAC. Obinutuzumab. Davis's Drug Guide. F.A. Davis Company; 2026. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110125/11/obinutuzumab. Accessed June 26, 2026.
Vallerand, A. H., & Sanoski, C. A. (2026). Obinutuzumab. In Davis's Drug Guide (20th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110125/11/obinutuzumab
Vallerand AHA, Sanoski CAC. Obinutuzumab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 June 26]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110125/11/obinutuzumab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - obinutuzumab
ID - 110125
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110125/11/obinutuzumab
PB - F.A. Davis Company
ET - 20
DB - Pediatrics Central
DP - Unbound Medicine
ER -

Davis's Drug Guide

